Single Antiplatelet After TAVR Lowers Risk

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

New findings from real-world experience support the shift in practice to single antiplatelet therapy after transcatheter aortic valve replacement.
Medscape Medical News